Passage Bio's S-4 Lays Bare the Cost of Its Reverse Merger with Remix Therapeutics: Existing Holders Left with Just 6%

summarizeSummary

Passage Bio's S-4 reveals that its stockholders will own just 6% of the combined company after a reverse merger with Remix Therapeutics, a clinical-stage biotech. The deal includes a $100 million concurrent financing and contingent value rights for Passage Bio holders.

check_boxKey Events · M&A and Partnerships · PASG

• Reverse Merger Terms Finalized

  In an all-stock deal, Passage Bio will merge with Remix Therapeutics. Based on an assumed exchange ratio of 0.1734, the company expects to issue approximately 27.0 million shares to Remix securityholders, leaving pre-merger Passage Bio stockholders with only about 6% of the combined company.

• Massive Dilution for Existing Holders

  Pro forma ownership breaks down as follows: Remix equityholders 65%, Concurrent Financing investors 29%, and Passage Bio equityholders just 6%. The implied combined company value is approximately $346 million, with Remix valued at $226 million and Passage Bio at $20 million (assuming $5 million net cash at closing).

• $100 Million Concurrent Financing

  Remix has secured a $100 million financing package—a $70 million equity subscription and $30 million in convertible notes—that will close immediately before the merger. These investors will receive approximately 29% of the combined company.

• Contingent Value Rights for Passage Bio Holders

  Each Passage Bio stockholder will receive one CVR per share, entitling them to 80% of certain product purchase fees from a GM1 license (through July 2028) and 100% of upfront fees from an MLD license (through December 2027), net of deductions. There is no assurance any payments will be made.

auto_awesomeAnalysis · PASG · Life Sciences

The S-4 registration statement from Passage Bio spells out the definitive terms of its reverse merger with private biotech Remix Therapeutics. For a company that had a going concern warning and had wound down operations, the deal is a lifeline—but it comes at a steep price. Existing Passage Bio stockholders will be diluted to roughly 6% ownership of the combined entity, while Remix equityholders claim 65% and new investors in a concurrent $100 million financing take 29%. The filing also details contingent value rights (CVRs) that offer Passage Bio stockholders a potential, though highly uncertain, future payout from legacy assets. Subject to stockholder approval, the merger is expected to close in Q4 2026.